- Home
- PMX vs PRLD Comparison
PMX vs PRLD Comparison
Compare PMX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMX
- PRLD
- Stock Information
- Founded
- PMX 2002
- PRLD 2016
- Country
- PMX United States
- PRLD United States
- Employees
- PMX N/A
- PRLD N/A
- Industry
- PMX Trusts Except Educational Religious and Charitable
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- PMX Finance
- PRLD Health Care
- Exchange
- PMX Nasdaq
- PRLD Nasdaq
- Market Cap
- PMX 269.1M
- PRLD 152.4M
- IPO Year
- PMX N/A
- PRLD 2020
- Fundamental
- Price
- PMX $8.15
- PRLD $2.58
- Analyst Decision
- PMX
- PRLD Hold
- Analyst Count
- PMX 0
- PRLD 3
- Target Price
- PMX N/A
- PRLD $5.33
- AVG Volume (30 Days)
- PMX 101.5K
- PRLD 370.3K
- Earning Date
- PMX 01-01-0001
- PRLD 10-30-2024
- Dividend Yield
- PMX 5.28%
- PRLD N/A
- EPS Growth
- PMX N/A
- PRLD N/A
- EPS
- PMX N/A
- PRLD N/A
- Revenue
- PMX N/A
- PRLD N/A
- Revenue This Year
- PMX N/A
- PRLD N/A
- Revenue Next Year
- PMX N/A
- PRLD N/A
- P/E Ratio
- PMX N/A
- PRLD N/A
- Revenue Growth
- PMX N/A
- PRLD N/A
- 52 Week Low
- PMX $6.09
- PRLD $1.66
- 52 Week High
- PMX $8.47
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- PMX 67.56
- PRLD 29.30
- Support Level
- PMX $7.95
- PRLD $2.69
- Resistance Level
- PMX $8.19
- PRLD $5.08
- Average True Range (ATR)
- PMX 0.10
- PRLD 0.53
- MACD
- PMX 0.01
- PRLD -0.26
- Stochastic Oscillator
- PMX 78.12
- PRLD 3.52
About PMX PIMCO Municipal Income Fund III of Beneficial Interest
PIMCO Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as transportation, healthcare, and others.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.